Beijing Kangchen Biological Technology

Beijing Kangchen Biological Technology is a Chinese biopharmaceutical company and a core subsidiary of Beijing Konruns Pharmaceutical. The company specializes in the discovery, development, and commercialization of innovative drugs, with a strategic focus on oncology, hematology, and surgical hemostasis. Its flagship product, Suling (Hemocoagulase Agkistrodon), is a proprietary hemostatic agent derived from snake venom that is widely utilized in clinical surgery across China. The company's research pipeline features KC1036, a multi-target kinase inhibitor currently in Phase 2 clinical trials for various advanced solid tumors, including esophageal and gastric cancers. Beijing Kangchen Biological Technology is committed to addressing unmet medical needs through high-tech biological innovation and rigorous clinical development.